C5 and paroxysmal nocturnal hemoglobinuria: Although eculizumab is highly effective in the treatment of patients with PNH, 11–27% of eculizumab-treated patients may experience breakthrough hemolysis due to suboptimal C5 inhibition, infections, surgery, or pregnancy [8–10].